Photobiomodulation Therapy: A Novel Therapeutic Approach to Alzheimer's Disease Made Possible by the Evidence of a Brain-Gut Interconnection

被引：2
作者：
Blivet, Guillaume [1 ]
Roman, Francois J. [2 ]
Lelouvier, Benjamin [3 ]
Ribiere, Celine [3 ]
Touchon, Jacques [4 ]
机构：
[1] REGEnLIFE, F-75008 Paris, France
[2] FRconsulting, F-34800 Clermont Lherault, France
[3] Vaiomer, F-31670 Labege, France
[4] Univ Montpellier, Fac Med, F-34000 Montpellier, France
来源：
JOURNAL OF INTEGRATIVE NEUROSCIENCE | 2024年 / 23卷 / 05期
关键词：
Alzheimer's disease; neurodegeneration; neuroinflammation; brain-gut axis; microbiota; microbiome; photobiomodulation; low-level laser therapy (LLLT); oxidative stress; mitochondria;
D O I：
10.31083/j.jin2305092
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
The evidence of brain-gut interconnections in Alzheimer's disease (AD) opens novel avenues for the treatment of a pathology for which no definitive treatment exists. Gut microbiota and bacterial translocation may produce peripheral inflammation and immune modulation, contributing to brain amyloidosis, neurodegeneration, and cognitive deficits in AD. The gut microbiota can be used as a potential therapeutic target in AD. In particular, photobiomodulation (PBM) can affect the interaction between the microbiota and the immune system, providing a potential explanation for its restorative properties in AD -associated dysbiosis. PBM is a safe, non-invasive, non -ionizing, and non -thermal therapy that uses red or near -infrared light to stimulate the cytochrome c oxidase (CCO, complex IV), the terminal enzyme of the mitochondrial electron transport chain, resulting in adenosine triphosphate synthesis. The association of the direct application of PBM to the head with an abscopal and a systemic treatment through simultaneous application to the abdomen provides an innovative therapeutic approach to AD by targeting various components of this highly complex pathology. As a hypothesis, PBM might have a significant role in the therapeutic options available for the treatment of AD.
引用
收藏
页数：6
相关论文
共 75 条
  • [1] Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, Et al., Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease, The Journal of Prevention of Alzheimer’s Disease, 9, pp. 197-210, (2022)
  • [2] van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Et al., Lecanemab in Early Alzheimer’s Disease, The New England Journal of Medicine, 388, pp. 9-21, (2023)
  • [3] Bhattacharjee S, Lukiw WJ., Alzheimer’s disease and the microbiome, Frontiers in Cellular Neuroscience, 7, (2013)
  • [4] Kang SS, Jeraldo PR, Kurti A, Miller MEB, Cook MD, Whitlock K, Et al., Diet and exercise orthogonally alter the gut microbiome and reveal independent associations with anxiety and cognition, Molecular Neurodegeneration, 9, (2014)
  • [5] Wang Y, Kasper LH., The role of microbiome in central nervous system disorders, Brain, Behavior, and Immunity, 38, pp. 1-12, (2014)
  • [6] Distrutti E, O'Reilly JA, McDonald C, Cipriani S, Renga B, Lynch MA, Et al., Modulation of intestinal microbiota by the pro-biotic VSL#3 resets brain gene expression and ameliorates the age-related deficit in LTP, PLoS ONE, 9, (2014)
  • [7] Vogt NM, Kerby RL, Dill-McFarland KA, Harding SJ, Merluzzi AP, Johnson SC, Et al., Gut microbiome alterations in Alzheimer’s disease, Scientific Reports, 7, (2017)
  • [8] Heston MB, Hanslik KL, Zarbock KR, Harding SJ, Davenport-Sis NJ, Kerby RL, Et al., Gut inflammation associated with age and Alzheimer’s disease pathology: a human cohort study, Scientific Reports, 13, (2023)
  • [9] Lee RL, Funk KE., Imaging blood-brain barrier disruption in neuroinflammation and Alzheimer’s disease, Frontiers in Aging Neuroscience, 15, (2023)
  • [10] Cassano P, Petrie SR, Hamblin MR, Henderson TA, Iosifescu DV., Review of transcranial photobiomodulation for major depressive disorder: targeting brain metabolism, inflammation, oxidative stress, and neurogenesis, Neurophotonics, 3, (2016)
12345678